Terril Brothers, Inc. Bristol Myers Squibb CO Transaction History

Terril Brothers, Inc.

$260 Million
Q2 2024

A detailed history of Terril Brothers, Inc. transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Terril Brothers, Inc. holds 151,263 shares of BMY stock, worth $7.97 Million. This represents 2.42% of its overall portfolio holdings.

Number of Shares

151,263

Previous 245,808 38.46%

Holding current value

$7.97 Million

Previous $13.3 Million 52.88%

% of portfolio

2.42%

Previous 4.95%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 09, 2024	SELL	$40.25 - $52.99 $3.81 Million - $5.01 Million	-94,545 Reduced 38.46%	151,263 $6.28 Million
Q1 2024 Apr 29, 2024	SELL	$47.98 - $54.4 $62,613 - $70,992	-1,305 Reduced 0.53%	245,808 $13.3 Million
Q4 2023 Feb 02, 2024	SELL	$48.48 - $57.85 $87,554 - $104,477	-1,806 Reduced 0.73%	247,113 $12.7 Million
Q3 2023 Nov 08, 2023	SELL	$57.89 - $64.73 $353,013 - $394,723	-6,098 Reduced 2.39%	248,919 $14.4 Million
Q2 2023 Aug 04, 2023	SELL	$63.71 - $70.74 $93,653 - $103,987	-1,470 Reduced 0.57%	255,017 $16.3 Million
Q1 2023 May 08, 2023	SELL	$65.71 - $74.53 $489,079 - $554,726	-7,443 Reduced 2.82%	256,487 $17.8 Million
Q4 2022 Jan 31, 2023	SELL	$68.48 - $81.09 $361,232 - $427,749	-5,275 Reduced 1.96%	263,930 $19 Million
Q3 2022 Nov 01, 2022	SELL	$0.13 - $76.84 $244 - $144,382	-1,879 Reduced 0.69%	269,205 $19.1 Million
Q2 2022 Aug 04, 2022	SELL	$72.62 - $79.98 $7.87 Million - $8.67 Million	-108,390 Reduced 28.56%	271,084 $20.9 Million
Q1 2022 May 10, 2022	SELL	$61.48 - $73.72 $590,208 - $707,712	-9,600 Reduced 2.47%	379,474 $27.7 Million
Q4 2021 Feb 07, 2022	SELL	$53.63 - $62.52 $364,308 - $424,698	-6,793 Reduced 1.72%	389,074 $24.3 Million
Q3 2021 Oct 29, 2021	SELL	$59.17 - $69.31 $607,675 - $711,813	-10,270 Reduced 2.53%	395,867 $23.4 Million
Q2 2021 Jul 27, 2021	SELL	$61.91 - $67.42 $514,781 - $560,597	-8,315 Reduced 2.01%	406,137 $27.1 Million
Q1 2021 Apr 23, 2021	SELL	$59.34 - $66.74 $831,353 - $935,027	-14,010 Reduced 3.27%	414,452 $26.2 Million
Q4 2020 Jan 28, 2021	SELL	$57.74 - $65.43 $740,804 - $839,466	-12,830 Reduced 2.91%	428,462 $26.6 Million
Q3 2020 Oct 28, 2020	SELL	$57.43 - $63.64 $575,735 - $637,991	-10,025 Reduced 2.22%	441,292 $26.6 Million
Q2 2020 Aug 04, 2020	BUY	$54.82 - $64.09 $883,040 - $1.03 Million	16,108 Added 3.7%	451,317 $26.5 Million
Q1 2020 May 12, 2020	SELL	$46.4 - $67.43 $457,272 - $664,522	-9,855 Reduced 2.21%	435,209 $24.3 Million
Q4 2019 Feb 05, 2020	SELL	$49.21 - $64.19 $634,415 - $827,537	-12,892 Reduced 2.82%	445,064 $28.6 Million
Q3 2019 Oct 25, 2019	SELL	$42.77 - $50.71 $273,642 - $324,442	-6,398 Reduced 1.38%	457,956 $23.2 Million
Q2 2019 Aug 05, 2019	SELL	$44.62 - $49.34 $278,651 - $308,128	-6,245 Reduced 1.33%	464,354 $21.1 Million
Q1 2019 Apr 29, 2019	SELL	$45.12 - $53.8 $987,676 - $1.18 Million	-21,890 Reduced 4.44%	470,599 $22.5 Million
Q4 2018 Feb 07, 2019	SELL	$48.76 - $63.23 $94,350 - $122,350	-1,935 Reduced 0.39%	492,489 $25.6 Million
Q3 2018 Oct 23, 2018	SELL	$55.19 - $62.25 $440,416 - $496,755	-7,980 Reduced 1.59%	494,424 $30.7 Million
Q2 2018 Aug 03, 2018	BUY	$50.53 - $62.98 $249,870 - $311,436	4,945 Added 0.99%	502,404 $27.8 Million
Q1 2018 May 03, 2018	SELL	$59.92 - $68.98 $487,449 - $561,152	-8,135 Reduced 1.61%	497,459 $31.5 Million
Q4 2017 Jan 23, 2018	SELL	$59.94 - $65.35 $173,526 - $189,188	-2,895 Reduced 0.57%	505,594 $31 Million
Q3 2017 Nov 07, 2017	BUY	$55.23 - $63.74 $28.1 Million - $32.4 Million	508,489	508,489 $32.4 Million

Others Institutions Holding BMY

# of Institutions

2,438

Shares Held

1.51B

Call Options Held

29.7M

Put Options Held

32.1M

View Full List

About BRISTOL MYERS SQUIBB CO

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $112B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

More about BMY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Terril Brothers, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Terril Brothers, Inc. with notifications on news.

Account

Terril Brothers, Inc. Bristol Myers Squibb CO Transaction History